ID   OE19
AC   CVCL_1622
SY   OE-19; JROECL 19; JROECL19; OEC19
DR   CLO; CLO_0008238
DR   EFO; EFO_0002308
DR   CLDB; cl3761
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471032
DR   BioSample; SAMN10988362
DR   cancercelllines; CVCL_1622
DR   Cell_Model_Passport; SIDM00479
DR   ChEMBL-Cells; CHEMBL3308462
DR   ChEMBL-Targets; CHEMBL1075555
DR   Cosmic; 871232
DR   Cosmic; 910079
DR   Cosmic; 978854
DR   Cosmic; 997860
DR   Cosmic; 1175878
DR   Cosmic; 1599342
DR   Cosmic; 1618819
DR   Cosmic; 1995600
DR   Cosmic-CLP; 910079
DR   DepMap; ACH-000679
DR   DSMZ; ACC-700
DR   DSMZCellDive; ACC-700
DR   ECACC; 96071721
DR   EGA; EGAS00001000978
DR   GDSC; 910079
DR   GEO; GSM827301
DR   GEO; GSM887475
DR   GEO; GSM888555
DR   GEO; GSM1264050
DR   GEO; GSM1264051
DR   GEO; GSM1264052
DR   GEO; GSM1264053
DR   GEO; GSM1264054
DR   GEO; GSM1264092
DR   GEO; GSM1264093
DR   GEO; GSM1264094
DR   GEO; GSM1264095
DR   GEO; GSM1264096
DR   GEO; GSM1670302
DR   IARC_TP53; 21600
DR   IGRhCellID; OE19
DR   LiGeA; CCLE_923
DR   LINCS_LDP; LCL-1796
DR   PharmacoDB; OE19_1194_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1622
DR   PubChem_Cell_line; CVCL_1622
DR   Wikidata; Q54931862
RX   PubMed=9010035;
RX   PubMed=15511476;
RX   PubMed=16364037;
RX   PubMed=20075370;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23795680;
RX   PubMed=24083764;
RX   PubMed=25070024;
RX   PubMed=25877200;
RX   PubMed=26512696;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
WW   https://www.phe-culturecollections.org.uk/media/115878/oe19-cell-line-profile.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476).
CC   Doubling time: ~50-60 hours (DSMZ=ACC-700).
CC   HLA typing: A*02:01,02:01; B*07:17,51:01; C*16:01,16:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn310Lysfs*27 (c.929dup) (c.929_930ins1); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=15.01%; Native American=0.16%; East Asian, North=1.83%; East Asian, South=0%; South Asian=11.79%; European, North=8.22%; European, South=62.99% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=20075370; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 9,11
ST   D16S539: 12,13
ST   D18S51: 12 (PubMed=25877200)
ST   D18S51: 12,13 (DSMZ; PubMed=20075370)
ST   D19S433: 13
ST   D21S11: 30
ST   D2S1338: 18,19
ST   D3S1358: 15,18
ST   D5S818: 11,14
ST   D7S820: 8
ST   D8S1179: 13,15
ST   FGA: 23,26
ST   Penta D: 9
ST   Penta E: 5,8
ST   TH01: 8,9
ST   TPOX: 8
ST   vWA: 16,17 (Cosmic-CLP; ECACC)
ST   vWA: 16,17,18 (DSMZ; PubMed=20075370; PubMed=25877200)
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   PubMed=9010035; DOI=10.1038/bjc.1997.42;
RA   Rockett J.C., Larkin K., Darnton S.J., Morris A.G., Matthews H.R.;
RT   "Five newly established oesophageal carcinoma cell lines: phenotypic
RT   and immunological characterization.";
RL   Br. J. Cancer 75:258-263(1997).
//
RX   PubMed=15511476; DOI=10.1016/j.athoracsur.2004.05.037;
RA   Dahlberg P.S., Jacobson B.A., Dahal G., Fink J.M., Kratzke R.A.,
RA   Maddaus M.A., Ferrin L.J.;
RT   "ERBB2 amplifications in esophageal adenocarcinoma.";
RL   Ann. Thorac. Surg. 78:1790-1800(2004).
//
RX   PubMed=16364037; DOI=10.1111/j.1442-2050.2006.00530.x;
RA   Su M., Chin S.-F., Li X.-Y., Edwards P.A.W., Caldas C.,
RA   Fitzgerald R.C.;
RT   "Comparative genomic hybridization of esophageal adenocarcinoma and
RT   squamous cell carcinoma cell lines.";
RL   Dis. Esophagus 19:10-14(2006).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=24083764; DOI=10.7314/APJCP.2013.14.8.4891;
RA   Li J.-C., Liu D., Yang Y., Wang X.-Y., Pan D.-L., Qiu Z.-D., Su Y.,
RA   Pan J.-J.;
RT   "Growth, clonability, and radiation resistance of esophageal
RT   carcinoma-derived stem-like cells.";
RL   Asian Pac. J. Cancer Prev. 14:4891-4896(2013).
//
RX   PubMed=25070024; DOI=10.1007/s00423-014-1235-1;
RA   Drenckhan A., Grob T., Dupree A., Dohrmann T., Mann O., Izbicki J.R.,
RA   Gros S.J.;
RT   "Esophageal carcinoma cell line with high EGFR polysomy is responsive
RT   to gefitinib.";
RL   Langenbecks Arch. Surg. 399:879-888(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26512696; DOI=10.3390/cancers7040881;
RA   O'Callaghan C., Fanning L.J., Barry O.P.;
RT   "Hypermethylation of MAPK13 promoter in oesophageal squamous cell
RT   carcinoma is associated with loss of p38delta MAPK expression.";
RL   Cancers (Basel) 7:2124-2133(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//